Munich - Delayed Quote EUR

Genscript Biotech Corp (G51.MU)

1.2505

+0.0040

+(0.32%)

At close: May 2 at 8:04:21 AM GMT+2

Asian Stocks Estimated Below Intrinsic Value In April 2025

As global markets navigate a complex landscape marked by trade tensions and monetary policy shifts, Asian indices are showing resilience, with Chinese stocks experiencing gains amid expectations of increased stimulus. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that align with intrinsic value assessments and broader economic conditions.

Simply Wall St. 12 days ago

GNNSF
ProBio Sets New Standard in GMP Plasmid DNA Manufacturing with Guaranteed ≥ 85% Supercoiled DNA, Fixed-Cost, Clinical-Grade Delivered in Just 3 Months

ProBio, a global contract development and manufacturing organization (CDMO), is pleased to announce the launch of its GMP Plasmid DNA manufacturing service at its state-of-the-art facility in Hopewell. This new service guarantees the delivery of clinical-grade plasmid DNA production from cell bank to batch release in just three months. This is a significantly faster manufacturing time than is typical and can help accelerate the development of gene and cell therapies.

PR Newswire 25 days ago

GNNSF
Asian Market Insights: 3 Stocks Estimated Below Intrinsic Value

As global markets grapple with inflation concerns and trade uncertainties, the Asian market presents a unique landscape where opportunities for investment can still be found. In this environment, identifying stocks that are potentially undervalued compared to their intrinsic value becomes crucial for investors seeking to navigate the complexities of current economic conditions.

Simply Wall St. last month

GNNSF

2371.TW

NWBTF
GenScript Biotech Corporation Reports FY 2024 Results

GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufacturing reported its financial results for the full year ended on December 31, 2024.

PR Newswire last month

GNNSF
3 Stocks That Might Be Trading Below Their Estimated Value

As global markets continue to navigate through a landscape marked by rising inflation and fluctuating interest rates, U.S. stock indexes are climbing toward record highs, with growth stocks outperforming their value counterparts. In this environment, identifying stocks that might be trading below their estimated value can present unique opportunities for investors looking to capitalize on potential market inefficiencies.

Simply Wall St. 2 months ago

GNNSF

SPIWF
GenScript's 2025 JPM Global Forum Concludes Successfully in San Francisco

GenScript Biotech, a global biotechnology leader in life science, biologics manufacturing, synthetic biology, and cell therapies announced the successful conclusion of its 2025 JPM Global Forum held on January 15 in San Francisco. The event, themed "Challenges and Opportunities of Cell and Gene Therapy in the New Era," attracted more than 700 attendees both in person and via live-stream, featuring a series of keynote speeches and panel discussions that offered insights into the future of cell an

PR Newswire 3 months ago

GNNSF
3 Leading Stocks Estimated To Be Up To 49.3% Below Their Intrinsic Value

In the current global market landscape, cooling inflation in the U.S. and robust bank earnings have driven major stock indexes higher, with value stocks outperforming growth shares significantly. Amid these developments, identifying undervalued stocks becomes crucial as they offer potential opportunities for investors looking to capitalize on discrepancies between market prices and intrinsic values.

Simply Wall St. 3 months ago

GNNSF

FITGF

ASMVF
3 Stocks That May Be Undervalued In December 2024

As global markets navigate a period of cautious optimism following the Federal Reserve's recent rate cut and ongoing political uncertainties, investors are closely watching for opportunities amid fluctuating indices. With U.S. stocks experiencing broad-based declines and European markets facing challenges from potential trade tariffs, the search for undervalued stocks becomes particularly relevant in this climate. Identifying potentially undervalued stocks requires careful consideration of a...

Simply Wall St. 4 months ago

GNNSF
GenScript Announces 4th Annual Biotech Global Forum in San Francisco

GenScript Biotech, a global biotechnology leader in life sciences, biologics manufacturing, synthetic biology, and cell therapies is proud to announce its 4th Annual Biotech Global Forum, scheduled for January 15, 2025, at the San Francisco Marriott Marquis.

PR Newswire 4 months ago

GNNSF
Transforming Plasmid DNA Purification: Automation That Delivers Optimal Yields and Low Endotoxin

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its Life Sciences subsidiary, GenScript, has launched a next generation DNA purification platform: The AmMag™ Quatro Mini-1100. This new instrument complements the widely acclaimed AmMag Quatro Maxi-1400, providing comprehensive solutions for both mini- and maxi-scale plasmid purification.

PR Newswire 4 months ago

GNNSF
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference in San Francisco in 2020, the forum has become a significant platform for advancing cell and gene therapy (CGT). This year's move to Europe underscores GenScript's commitment to driving the global CGT innovation and fostering international col

PR Newswire 5 months ago

GNNSF
GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment.

PR Newswire 5 months ago

GNNSF
Seasoned Marketing Executive Joins GenScript as Chief Marketing Officer

GenScript Biotech, a global leader in biotechnology leveraging advanced, proprietary gene synthesis and life-science technologies, announced today that Mrs. Aylin Kosova Bilgin has joined as the first-ever Chief Marketing Officer for GenScript Life Science Group.

PR Newswire 5 months ago

GNNSF
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia

GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site and logistics center in Sydney, Australia. This strategic expansion represents a significant milestone in GenScript's continued commitment to supporting the rapid growth of the biotechnology sector in Australia. It also underscores the company's determination to strengthen GenScript's presence in the Asia-Pacific region and globally, advancin

PR Newswire 5 months ago

GNNSF
Genscript Biotech Corp (GNNSF) (H1 2024) Earnings Call Highlights: Robust Revenue Growth Amidst ...

Genscript Biotech Corp (GNNSF) reports a 43.5% revenue increase, narrowing net losses, and strong performance in Legend, despite ProBio setbacks and geopolitical tensions.

GuruFocus.com 6 months ago

GNNSF
GenScript Appoints New Board Members to Drive Global Growth

GenScript Biotech Corporation ("GenScript"), a global leader in life sciences products and services, announced the appointment of Dr. Ross Allen Grossman as a Non-Executive Director and Dr. Alphonse Galdes as an Independent Non-Executive Director. These appointments not only further diversify the Group's Board but also highlight GenScript's commitment to building an international, diverse, and highly specialized corporate governance team. With the addition of these two directors, the company is

PR Newswire 7 months ago

GNNSF
GenScript Biotech Reports First Half 2024 Results

GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufacture, today reported its first half 2024 financial results for the six months ended June 30, showcasing impressive revenue growth, significant improvements in gross profit, and strategic advances across its business segments. GenScript is also deepening its commitment to environmental, social, and governance (ESG) practices, marking a significant step towards sustainable

PR Newswire 8 months ago

GNNSF
Genscript Biotech Leads Trio Of Value Stocks On SEHK Estimated Below Market Valuations

As global markets navigate through mixed economic signals and varied regional performances, the Hong Kong market has shown resilience amidst broader Asian market challenges. This context sets a compelling stage for investors to consider undervalued stocks, such as Genscript Biotech, which may present opportunities in an environment where discerning value is key.

Simply Wall St. 9 months ago

GNNSF

BSDGF

BSDGY
Exploring Undervalued SEHK Stocks With Intrinsic Discounts Ranging From 41.1% To 48.9%

Amidst a mixed landscape for global markets, Hong Kong's Hang Seng Index has shown resilience with a modest gain of 0.46% in a holiday-shortened week, reflecting nuanced investor sentiment towards the region's economic outlook. In such an environment, identifying undervalued stocks can be particularly compelling as they may represent opportunities for investors seeking value in a market characterized by cautious optimism and uneven economic indicators.

Simply Wall St. 9 months ago

1209.HK

GNNSF

BAIGF
Exploring Undervalued Opportunities: 3 SEHK Stocks With Intrinsic Discounts Ranging From 27.6% To 41.4%

Amidst a backdrop of fluctuating global markets, the Hong Kong stock market presents intriguing opportunities, evidenced by its recent modest gains. As investors seek value in a landscape marked by mixed economic signals, identifying undervalued stocks becomes a prudent strategy to explore potential growth avenues.

Simply Wall St. 10 months ago

BAIGF

IGGGF

GNNSF

Performance Overview

Return	G51.MU	HANG SENG INDEX (^HSI)
YTD	+2.50%	+12.19%
1-Year	-10.04%	+23.60%
3-Year	-49.43%	+6.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Genscript Biotech Corp (G51.MU)

Asian Stocks Estimated Below Intrinsic Value In April 2025

ProBio Sets New Standard in GMP Plasmid DNA Manufacturing with Guaranteed ≥ 85% Supercoiled DNA, Fixed-Cost, Clinical-Grade Delivered in Just 3 Months

Asian Market Insights: 3 Stocks Estimated Below Intrinsic Value

GenScript Biotech Corporation Reports FY 2024 Results

3 Stocks That Might Be Trading Below Their Estimated Value

GenScript's 2025 JPM Global Forum Concludes Successfully in San Francisco

3 Leading Stocks Estimated To Be Up To 49.3% Below Their Intrinsic Value

3 Stocks That May Be Undervalued In December 2024

GenScript Announces 4th Annual Biotech Global Forum in San Francisco

Transforming Plasmid DNA Purification: Automation That Delivers Optimal Yields and Low Endotoxin

The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer

Seasoned Marketing Executive Joins GenScript as Chief Marketing Officer

GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia

Genscript Biotech Corp (GNNSF) (H1 2024) Earnings Call Highlights: Robust Revenue Growth Amidst ...

GenScript Appoints New Board Members to Drive Global Growth

GenScript Biotech Reports First Half 2024 Results

Genscript Biotech Leads Trio Of Value Stocks On SEHK Estimated Below Market Valuations

Exploring Undervalued SEHK Stocks With Intrinsic Discounts Ranging From 41.1% To 48.9%

Exploring Undervalued Opportunities: 3 SEHK Stocks With Intrinsic Discounts Ranging From 27.6% To 41.4%

Performance Overview